After Ethics committee’s approval, clinical study will be registered on CTRI website. Both male and female subjects of age between 18 to 65 years of age (both inclusive) attending outpatient department of study site(s) will be screened for eligibility criteria. The recruitment will be done in ratio of 75:25% Male to female respectively.

On screening visit, a written informed consent will be obtained from subjects for their participation in the study. Subject’s demographic details will be taken. Subject will undergo clinical examination. Subject’s medical, surgical and treatment history will be taken. Subject’s current medication if any will be noted in the case record from (CRF). Subject’s vitals will be recorded. The subject will be considered for further evaluation as per the inclusion and exclusion criteria.

Subject’s blood sample will be collected at the respective study centers for laboratory testing i.e. CBC, ESR, Hb%, Thyroid function test, Liver Function Tests, Lipid Profile, Renal Function test, Random sugar, HbA1c. Urine Routine tests will be done. During screening visit and the entire study duration subjects will be advised to refrain from antioxidant agents, vitamins, anti-inflammatory    drugs,    hormones,   Nutraceutical, Ayurvedic,    Siddha,    Unani,  herbal /homeopathic medicines.

On baseline visit, subject will be recruited in the study if he or she meets all the inclusion criteria. Subjects will then be randomized to one of the two study groups as per the computer generated randomization list. Subjects will be asked for occurrence of any adverse event during screening period. Subject will undergo clinical examination. Subject’s vitals will be recorded. Subject’s Daily activity, Endurance levels, Perceived stress levels and number of events of recurrent UTI/RTI etc. will be recorded. Subject’s Anthropometric analysis will be performed. Following questionnaires will be assessed like Quality of life (Physical, mental and social) General Health Questionnaire-28 (GHQ-28), digestive behavior assessment, mood behavior, sleep quality questionnaire.

 At baseline visit and at every follow up visit (except last follow up visit), as per computer generated randomization list, subjects will be provided with containers each containing 350 gms (300 gms for 30 days + additional 50 gms for use if follow up is delayed maximum up to 5 days) of either ‘Protein Supplement’ or Standard. Subject will be advised to consume given supplement in a dose of 10gms in the morning with 150 ml milk for 3 months. Subject will be advised to continue her concomitant medication other than antioxidant agents, weight loss management, vitamins, anti-inflammatory drugs, hormones, Nutraceutical, Ayurvedic, Siddha, Unani, herbal /homeopathic medicines etc. The record of concomitant medication will be kept in the CRF.

 Subjects will be called at respective study sites for follow up visits after every month up to 3 months after the baseline visit. On every follow up visit, Subject will undergo clinical examination. Subject’s vitals will be recorded. Subject’s Daily activity, Perceived stress levels and number of events of recurrent UTI/RTI etc. will be recorded. Subject’s Anthropometric analysis will be performed. Following questionnaires will be assessed like Quality of life (Physical, mental and social) General Health Questionnaire-28 (GHQ-28), digestive behavior assessment, mood behavior, sleep quality questionnaire.

 On third follow up visit (i.e. Day 90) Subject’s Daily activity, Endurance levels (steppers test), Perceived stress levels and number of events of recurrent UTI/RTI etc. will be recorded. Subject’s blood sample will be collected at the respective study centers for laboratory testing i.e. CBC, ESR, Hb%, Thyroid function test, Liver Function Tests, Lipid Profile, Renal Function test, Random sugar, HbA1c. Urine Routine tests will be done. Subject’s Anthropometric analysis will be performed. Subject will be assessed for applicable biochemical analysis and safety parameters. Following questionnaires will be assessed like Quality of life (Physical, mental and social) General Health Questionnaire-28 (GHQ-28), digestive behavior assessment, mood behavior, sleep quality questionnaire. Subject’s safety biochemical parameters along with the clinical examination will be performed. Adverse events will be critically evaluated. After completion of 3 months of study treatment, all the subjects will be asked to stop trial medications and take advice of investigator for further treatment.

 Global assessment of overall improvement will be done by subject and investigator on last follow up visit.  Palatability with dosage compliance will be assessed by the investigator and by subject of test product from baseline to end of the study. All the subjects will be closely monitored for any adverse event starting from baseline visit till the end of the study visit.